Now showing items 1-3 of 3

    • FDA approved fused pyrimidine-based drugs 

      Thakur, Shikha; Ansari, Arshad J.; Joshi, Gaurav (Elsevier, 2022-10-14)
      The present chapter is a compilation and analysis of USFDA approved small drug candidates about fused pyrimidine pharmacophore. Out of 63 drugs approved so far, nearly 38% of drugs are approved for chemotherapeutic treatment ...
    • Role of Hedgehog and Hippo signaling pathways in cancer: A special focus on non-coding RNAs 

      Sharma, Uttam; Tuli, Hardeep Singh; Uttam, Vivek; Choudhary, Renuka; Sharma, Bunty; Sharma, Ujjawal; Prakash, Hridayesh; Jain, Aklank (Academic Press, 2022-10-28)
      Despite advanced clinical and translational oncology research, mortality rates are still increasing worldwide. Recently, a class of non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and ...
    • Toxicophore exploration as a screening technology for drug design and discovery: techniques, scope and limitations 

      Singh, Pankaj Kumar; Negi, Arvind; Gupta, Pawan Kumar; Chauhan, Monika; Kumar, Raj (Springer Verlag, 2016)
      Toxicity is a common drawback of newly designed chemotherapeutic agents. With the exception of pharmacophore-induced toxicity (lack of selectivity at higher concentrations of a drug), the toxicity due to chemotherapeutic ...